74 related articles for article (PubMed ID: 3181446)
1. The use of serum carcinoembryonic antigen to assess therapeutic response in locally advanced and metastatic breast cancer: a prospective study with external review.
Williams MR; Turkes A; Pearson D; Twining P; Griffiths K; Blamey RW
Eur J Surg Oncol; 1988 Oct; 14(5):417-22. PubMed ID: 3181446
[TBL] [Abstract][Full Text] [Related]
2. Serum ferritin as a marker of therapeutic response in stage III and IV breast cancer.
Williams MR; Turkes A; Pearson D; Griffiths K; Blamey RW
Eur J Surg Oncol; 1990 Feb; 16(1):22-7. PubMed ID: 2137790
[TBL] [Abstract][Full Text] [Related]
3. Megestrol acetate v tamoxifen in advanced breast cancer: a phase III trial of the Piedmont Oncology Association (POA).
Muss HB; Paschold EH; Black WR; Cooper MR; Capizzi RL; Christian R; Cruz JM; Jackson DV; Stuart JJ; Richards F
Semin Oncol; 1985 Mar; 12(1 Suppl 1):55-61. PubMed ID: 3883503
[TBL] [Abstract][Full Text] [Related]
4. [Carcinoembryonic antigens (CEA) in patients with metastatic breast cancer under endocrine and therapeutic treatment (author's transl)].
Pompecki R; Schröder G; Garbrecht M; Frahm H
Dtsch Med Wochenschr; 1978 Apr; 103(14):620-2. PubMed ID: 639696
[TBL] [Abstract][Full Text] [Related]
5. Megestrol acetate v tamoxifen in advanced breast cancer in postmenopausal patients.
Morgan LR
Semin Oncol; 1985 Mar; 12(1 Suppl 1):43-7. PubMed ID: 3975652
[TBL] [Abstract][Full Text] [Related]
6. Carcinoembryonic antigen: an invaluable marker for advanced breast cancer.
Pathak KA; Khanna R; Khanna HD; Khanna S; Gupta S; Khanna NN
J Postgrad Med; 1996; 42(3):68-71. PubMed ID: 9715319
[TBL] [Abstract][Full Text] [Related]
7. [Clinical study of the measurement of tissue polypeptide antigen in patients with breast cancer].
Fukunaga M; Otsuka N; Yanagi M; Sone T; Muranaka A; Yanagimoto S; Tomomitsu T; Morita R; Ohama T; Sonoo H
Gan No Rinsho; 1985 Jul; 31(8):923-8. PubMed ID: 4032770
[TBL] [Abstract][Full Text] [Related]
8. [Radioimmunoassay of carcinoembryonic antigen in the evaluation of the effectiveness of breast cancer treatment].
Polevaia EB; Ivanov VM; Koposova TL; Gabuniia RI; Chinareva IV
Vopr Onkol; 1984; 30(4):23-9. PubMed ID: 6730403
[TBL] [Abstract][Full Text] [Related]
9. Preoperative serum carcinoembryonic antigen level as a predictive factor of recurrence after curative resection of colorectal cancer.
Takagawa R; Fujii S; Ohta M; Nagano Y; Kunisaki C; Yamagishi S; Osada S; Ichikawa Y; Shimada H
Ann Surg Oncol; 2008 Dec; 15(12):3433-9. PubMed ID: 18846401
[TBL] [Abstract][Full Text] [Related]
10. A phase III trial comparing anastrozole (1 and 10 milligrams), a potent and selective aromatase inhibitor, with megestrol acetate in postmenopausal women with advanced breast carcinoma. Arimidex Study Group.
Buzdar AU; Jones SE; Vogel CL; Wolter J; Plourde P; Webster A
Cancer; 1997 Feb; 79(4):730-9. PubMed ID: 9024711
[TBL] [Abstract][Full Text] [Related]
11. Molecular detection of disseminated breast cancer cells in the bone marrow of early breast cancer patients using quantitative RT PCR for CEA.
Janku F; Srovnal J; Korinkova G; Novotny J; Petruzelka L; Power D; Matous B; Hajduch M
Neoplasma; 2008; 55(4):317-22. PubMed ID: 18505343
[TBL] [Abstract][Full Text] [Related]
12. Serial carcinoembryonic antigen (CEA) determinations in the management of patients with breast cancer.
Staab HJ; Ahlemann LM; Koch HL; Anderer FA
Oncodev Biol Med; 1980; 1(3):151-60. PubMed ID: 7279702
[TBL] [Abstract][Full Text] [Related]
13. Serial carcinoembryonic antigen (CEA) determinations in the management of metastatic breast cancer.
Lamerz R; Leonhardt A; Ehrhart H; von Lieven H
Oncodev Biol Med; 1980; 1(2):123-35. PubMed ID: 7279699
[TBL] [Abstract][Full Text] [Related]
14. Rhythmic fluctuations of CEA serum levels in breast cancer patients.
Jäger W; Diedrich M; Sauerbrei W; Wildt L
Anticancer Res; 1987; 7(4B):711-5. PubMed ID: 3674759
[TBL] [Abstract][Full Text] [Related]
15. An objective biochemical assessment of therapeutic response in metastatic breast cancer: a study with external review of clinical data.
Williams MR; Turkes A; Pearson D; Griffiths K; Blamey RW
Br J Cancer; 1990 Jan; 61(1):126-32. PubMed ID: 2137007
[TBL] [Abstract][Full Text] [Related]
16. A re-evaluation of carcinoembryonic antigen (CEA) as a serum marker for breast cancer: a prospective longitudinal study.
Guadagni F; Ferroni P; Carlini S; Mariotti S; Spila A; Aloe S; D'Alessandro R; Carone MD; Cicchetti A; Ricciotti A; Venturo I; Perri P; Di Filippo F; Cognetti F; Botti C; Roselli M
Clin Cancer Res; 2001 Aug; 7(8):2357-62. PubMed ID: 11489813
[TBL] [Abstract][Full Text] [Related]
17. Phase II study of vorozole (R83842), a new aromatase inhibitor, in postmenopausal women with advanced breast cancer in progression on tamoxifen.
Goss PE; Clark RM; Ambus U; Weizel HA; Wadden NA; Crump M; Walde D; Tye LM; De Coster R; Bruynseels J
Clin Cancer Res; 1995 Mar; 1(3):287-94. PubMed ID: 9815984
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of the relationship between serum carcinoembryonic antigen level and treatment outcome in surgically resected clinical-stage I patients with non-small-cell lung cancer.
Hotta K; Segawa Y; Takigawa N; Kishino D; Saeki H; Nakata M; Mandai K; Eguchi K
Anticancer Res; 2000; 20(3B):2177-80. PubMed ID: 10928173
[TBL] [Abstract][Full Text] [Related]
19. Decline in serum carcinoembryonic antigen and cytokeratin 19 fragment during chemotherapy predicts objective response and survival in patients with advanced nonsmall cell lung cancer.
Ardizzoni A; Cafferata MA; Tiseo M; Filiberti R; Marroni P; Grossi F; Paganuzzi M
Cancer; 2006 Dec; 107(12):2842-9. PubMed ID: 17103443
[TBL] [Abstract][Full Text] [Related]
20. Carcinoembryonic-like substance in breast fluid discharge in benign and malignant breast disease and in milk of lactating women.
Kahana L; Bartal AH; Yechieli H; Guttman I; Sheinfeld M
Isr J Med Sci; 1981 Nov; 17(11):1035-40. PubMed ID: 7319791
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
